Long-term efficacy and safety of vedolizumab compared with infliximab in biologic-naive ulcerative colitis: a systematic review and meta-analysis
Intestinal Research · 27.07.2026
DOI: 10.5217/ir.2026.00100 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Intestinal Research, online erschienen am 27.07.2026. Verfasst von Akhil Deepak Vatvani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, NYC Health + Hospitals/Lincoln, New York, NY, USA. vatvania@nychhc.org. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, NYC Health + Hospitals/Lincoln, New York, NY, USA. vatvania@nychhc.org.
- Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
- Department of Internal Medicine, NYC Health + Hospitals/Lincoln, New York, NY, USA.
- Department of Gastroenterology, Baystate Franklin Medical Center, Greenfield, MA, USA.
Zitieren
APA
Vatvani, A. D., Hariyanto, T. I., Mosquera, D. G., & Stephanie, S. (2026). Long-term efficacy and safety of vedolizumab compared with infliximab in biologic-naive ulcerative colitis: a systematic review and meta-analysis. Intestinal Research. https://doi.org/10.5217/ir.2026.00100
Vancouver
Vatvani AD, Hariyanto TI, Mosquera DG, Stephanie S. Long-term efficacy and safety of vedolizumab compared with infliximab in biologic-naive ulcerative colitis: a systematic review and meta-analysis. Intestinal Research. 2026. doi:10.5217/ir.2026.00100
BibTeX
@article{Vatvani2026,
author = {Vatvani, Akhil Deepak and Hariyanto, Timotius Ivan and Mosquera, Daniel Gonzalez and Stephanie, Stephanie},
title = {Long-term efficacy and safety of vedolizumab compared with infliximab in biologic-naive ulcerative colitis: a systematic review and meta-analysis},
journal = {Intestinal Research},
year = {2026},
doi = {10.5217/ir.2026.00100}
}
EUVIMED